308nm UVB vs. Other Treatments — Clinical Comparison for Vitiligo, Psoriasis & Eczema
This page compares 308nm targeted UVB phototherapy with the most common alternative treatments for vitiligo, psoriasis, and eczema. Comparisons are based on published clinical literature and standard dermatology practice. The goal is to help patients and caregivers make informed treatment decisions — not to advocate for any single approach.
308nm Targeted UVB vs. Narrowband UVB (311–313nm Full-Body Panels
| Factor | 308nm Targeted (Home Device) | Narrowband UVB (311nm Full-Body Panel) |
|---|---|---|
| Wavelength | 308nm (single wavelength, highest therapeutic efficacy for melanocyte stimulation) | 311–313nm broadened spectrum |
| Coverage | Targeted — 20–30 cm² per position, applied only to affected patches | Whole-body or large-area exposure including healthy skin |
| Cumulative UV dose to healthy skin | Minimal — healthy skin is not exposed | High — entire skin surface receives UV at each session |
| Best suited for | Localized patches (vitiligo, psoriasis, eczema); treatable area under ~20% BSA | Widespread disease affecting >20% body surface area |
| Setting | At home, FDA 510(k) cleared | Clinic or specialized home panels (expensive, large) |
| Cost | $479 one-time device cost | $150–$400 per clinic session; or $2,000–$5,000 for home panel |
| Session frequency | 3–5× per week at home | 2–3× per week at clinic |
| Efficacy for localized vitiligo | Comparable or superior to narrowband UVB for localized patches in clinical studies | Well-established; standard of care for widespread vitiligo |
Summary: For localized patches covering less than 20% of body surface, targeted 308nm delivers therapeutic UV only where needed, reducing cumulative UV load to healthy skin. For widespread disease, whole-body narrowband UVB panels are more practical.
308nm Targeted UVB vs. Clinic Excimer Laser (308nm)
| Factor | 308nm Home LED (e.g., Tendly Light) | 308nm Excimer Laser (Clinic) |
|---|---|---|
| Wavelength | 308nm | 308nm (identical wavelength) |
| Intensity | 15–25 mW/cm² | 50–150+ mW/cm² |
| Time per dose | Longer per session (lower intensity) | Shorter per session (higher intensity) |
| Cumulative efficacy | Comparable in trials using matched total dose over a treatment course | Well-established; higher intensity allows faster dose delivery |
| Frequency | 3–5× per week at home | Typically 2–3× per week at clinic, constrained by appointment availability |
| Cost per week | ~$0 (device already purchased) | $300–$800+ per week (2–3 sessions at $150–$400/session) |
| Accessibility | Treat at home on your schedule | Requires clinic proximity and appointment availability |
| Real-world adherence | Higher — no travel, no scheduling barrier | Lower — 2–3 clinic trips per week is a significant burden |
Summary: Clinic excimer lasers deliver the same 308nm wavelength at higher intensity, reducing session time. However, the real-world advantage of home treatment is adherence — the most consistent predictor of treatment outcome. At $300–$800/week in clinic costs, a home device pays for itself in under two weeks of treatment.
308nm UVB vs. Topical Corticosteroids (Vitiligo and Psoriasis)
| Factor | 308nm Targeted UVB | Topical Corticosteroids |
|---|---|---|
| Mechanism | Stimulates melanocyte activity (vitiligo); suppresses inflammatory cascade (psoriasis) | Suppresses local inflammation; reduces immune signaling |
| Repigmentation (vitiligo) | Evidence-based — stimulates actual melanocyte return | Some repigmentation possible with potent steroids; evidence weaker than UVB |
| Plaque clearance (psoriasis) | Effective for localized plaques; addresses underlying inflammatory mechanism | Effective short-term; plaques commonly return after stopping |
| Skin thinning risk | No — UVB does not cause skin atrophy | Yes — prolonged use causes skin thinning, telangiectasias, striae |
| Appropriate duration | Courses of weeks to months; maintenance possible long-term | Short courses recommended; risks increase with duration of use |
| Sensitive area use | Usable on face and skin folds with dose adjustment | Only weak steroids safe for face and skin folds long-term |
| Systemic absorption | None | Possible with extensive use, especially in children |
Summary: Topical steroids are effective short-term anti-inflammatory agents, but long-term use carries significant risks including skin atrophy. Targeted UVB addresses the underlying mechanisms driving both vitiligo and psoriasis without skin thinning risk. Many dermatologists use phototherapy as the primary treatment for localized disease, using topicals only as adjuncts during flares.
308nm UVB vs. Calcineurin Inhibitors (Tacrolimus / Pimecrolimus)
| Factor | 308nm Targeted UVB | Topical Calcineurin Inhibitors (TCIs) |
|---|---|---|
| Common agents | — | Tacrolimus (Protopic), Pimecrolimus (Elidel) |
| Primary use | Vitiligo, psoriasis, eczema | Vitiligo, eczema (off-label for both) |
| Mechanism | Stimulates melanocyte activity; immune modulation | Inhibits T-cell activation; reduces local immune response |
| Repigmentation evidence | Strong; well-established clinical evidence | Moderate; some evidence for facial vitiligo especially |
| Combination with UVB | — | TCIs + UVB often used together with additive benefit |
| Black box warning | None | FDA black box warning for theoretical malignancy risk with long-term use (evidence debated) |
| Skin atrophy | No | No (advantage over steroids) |
Summary: TCIs and targeted UVB are often used together — TCI applied to the patch before a UVB session has shown additive repigmentation results in several trials. Neither causes skin thinning, making this combination appropriate for facial patches where steroids carry more risk.
308nm UVB vs. PUVA Therapy
| Factor | 308nm Targeted UVB | PUVA (Psoralen + UVA) |
|---|---|---|
| UV type | UVB (308nm) | UVA (320–400nm) + psoralen photosensitizer |
| Psoralen required | No | Yes — oral or topical (significantly increases photosensitivity) |
| Session preparation | None | Oral psoralen: 2-hour wait before treatment; protective eyewear required for 24 hours post-session. Topical: applied immediately before treatment. |
| Skin cancer risk | Low — targeted delivery minimizes healthy skin exposure | Higher — PUVA is associated with increased squamous cell carcinoma risk with cumulative exposure; long-term monitoring required |
| Nausea risk | None | Oral psoralen commonly causes nausea |
| Home use | Yes, FDA-cleared devices available | No — PUVA requires clinic setting due to psoralen handling and monitoring requirements |
| Efficacy | Well-established; preferred for localized disease | Historically effective; now largely replaced by narrowband UVB and targeted devices due to superior safety profile of UVB |
Summary: PUVA was a mainstay of phototherapy for decades but has been largely replaced by narrowband UVB and targeted 308nm for most indications, due to UVB's better long-term safety profile (no associated squamous cell carcinoma risk, no psoralen required). PUVA remains useful for specific cases where UVB has not achieved adequate response.
308nm UVB vs. Biologics (Psoriasis)
| Factor | 308nm Targeted UVB | Biologics (IL-17, IL-23, TNF inhibitors) |
|---|---|---|
| Mechanism | Local immune modulation at treatment site | Systemic inhibition of specific immune pathways |
| Best for | Localized plaque psoriasis (<10–15% BSA) | Moderate-to-severe widespread psoriasis (>10% BSA or affecting quality of life significantly) |
| Administration | Home self-treatment; no injections | Subcutaneous injection (self-administered) or IV infusion |
| Cost | $479 one-time | $15,000–$50,000+ per year; typically requires insurance authorization |
| Infection risk | None | Increased risk of serious infections; screening required before initiation |
| Combination use | Can be combined with topicals and some biologics | Generally not combined with other immunosuppressants |
| Speed of response | 4–12 weeks | Often faster initial clearing (4–8 weeks with IL-17/IL-23 inhibitors) |
Summary: Biologics and targeted UVB address different disease severities. For well-defined localized plaques, targeted phototherapy is an effective, low-risk, low-cost intervention. For moderate-to-severe widespread psoriasis affecting quality of life, biologics may be more appropriate. Many patients use targeted phototherapy for residual localized plaques while managing systemic disease with biologics.
Which Treatment Is Right for You?
Treatment selection should always involve your dermatologist. As a general framework:
- Localized vitiligo or psoriasis patches (under ~15% body surface) — Targeted 308nm UVB is a well-supported first or second-line option, either alone or combined with topicals.
- Widespread disease — Whole-body narrowband UVB panels or systemic/biologic therapy are typically more practical.
- Long-term use concerns — Targeted UVB has a better long-term safety profile than corticosteroids, PUVA, or systemic immunosuppressants for localized disease.
- Clinic access or cost barriers — Home-cleared devices like Tendly Light provide clinic-equivalent wavelength therapy without the scheduling and cost burden of regular clinic visits.
Medical disclaimer: This comparison is for informational purposes only. Treatment decisions should always be made in consultation with a qualified dermatologist based on your individual medical history, disease severity, and circumstances.
Learn about Tendly Light — FDA 510(k) Cleared 308nm Home Device →